DIRS.INFO The most relevant business & tech news

Venkatakrishnan's intervention underscores the pressure that the British bank is under to protect its U.S. investment banking franchise. Venkatakrishnan promised during the meeting to invest in the investment banking business to boost morale, the sources said. Miller left Barclays to join Jefferies last month, while Barclays only announced a new role for Astier this week, naming him global head of financial sponsors. Still, the exodus that Venkatakrishnan and other Barclays executives have been trying to stem has continued apace. But it was its consumer, cards and payments division, rather than investment banking, that led the charge.

Persons: C.S, Venkatakrishnan, dealmakers, Cathal Deasy, Morgan Stanley, Taylor Wright, Marco Valla, Deasy, John Miller, Jean, Francois Astier, Miller, Jefferies, Jim Rossman, Christopher Ludwig, Pete Contrucci, Evan Rothenberg, Daniel Kerstein, Contrucci, Rothenberg, Kerstein, Milana Vinn, Abigail Summerville, David Carnevali, Svea Herbst, Bayliss, Anirban Sen, Greg Roumeliotis, Christopher Cushing Organizations: YORK, Barclays, Citigroup Inc, UBS Group AG, Jefferies Financial Group Inc, Reuters, Credit Suisse Group AG, UBS, Lazard Ltd, Credit Suisse, Svea, Thomson Locations: Americas, Europe, Middle East, Africa, United States, New York, Rhode Island

☆ Analysis: Amgen's antitrust woes spur wider pharmaceutical deal fears
▼ + stars: | 2023-05-17 | by ( David Carnevali | ) www.reuters.com time to read: +4 min

Even shares of drug companies that do not have pending deals but are seen by analysts and investors as potential acquisition targets were hit. FTC officials did not respond to a request for comment on whether they planned to challenge any other pharmaceutical acquisitions. "We could see similar challenges to the Pfizer/Seagen deal" BMO analysts wrote in a note, arguing that the FTC could target other major drug companies with the resources to engage in bundling. UNDER THE RADARConversely, investors and analysts are hoping that smaller pharmaceutical acquisitions will continue to fly under the radar of regulators. Reporting by David Carnevali in New York; Editing by Greg Roumeliotis and Jamie FreedOur Standards: The Thomson Reuters Trust Principles.

The buyout consortium has turned to other private equity firms to help fund the deal as direct lenders, one of the sources added. There is no certainty that Warburg Pincus and Advent will successfully complete negotiations to acquire the unit and Baxter may still opt to sell to another bidder or keep the business, according to the sources. Baxter, Warburg and Advent did not immediately respond to requests for comment. Baxter's biopharma solutions unit supports drugmakers in the formulation, development and commercialization of drugs typically given by infusion or injection, such as biologics and vaccines. The company said dialysis operations, which are a part of Baxter's renal care unit, had become a drag on its margin.

Emerson outbid other bidders including Fortive Corp (FTV.N) and Keysight Technologies Inc (KEYS.N) in the final stages of a sale process for National Instruments with an offer of about $60 per share, the sources said. National Instruments launched a formal sale process in January after Emerson threatened to challenge its board if it did not engage in deal negotiations. Emerson dropped its hostile bid once the auction for National Instruments got underway. Reuters first reported in March that Emerson, Fortive and Keysight were through to the final round of bidding for National Instruments, after breaking news of Emerson's interest in January. Austin, Texas-based National Instruments specializes in the production of automated testing and measurement tools for the semiconductor, transportation, aerospace and defense industries.

☆ Veritas, Carlyle end talks on Cotiviti stake sale - source
▼ + stars: | 2023-04-12 | by ( ) www.reuters.com time to read: +1 min

April 11 (Reuters) - Veritas Capital ended talks with Carlyle Group Inc (CG.O) to buy a 50% stake in private healthcare technology firm Cotiviti Inc on valuation grounds, a source familiar with the matter said. Carlyle wasn't ready to stick to the valuation that had previously been discussed in the current market conditions and submitted a revised bid in recent days, which Veritas rejected, the source said. In February, Reuters reported that Carlyle was in talks to buy a portion of Cotiviti from Veritas Capital at a valuation of around $15 billion. Cotiviti, which went public in 2016, was acquired by Veritas in 2018 in a take-private deal valued at $4.9 billion, as the private equity firm looked to expand its Verscend healthcare IT business. Carlyle and Veritas declined to comment, while Cotiviti did not immediately respond to a Reuters' request for comment.

☆ Exclusive: ICU Medical to compete against GE Healthcare for Medtronic units -sources
▼ + stars: | 2023-03-29 | by ( David Carnevali | ) www.reuters.com time to read: +2 min

GE Healthcare and private equity firms Carlyle Group Inc (CG.O) and Clayton, Dubilier & Rice (CD&R), which have been pursuing rival offers separately, are also through to the second round, the sources added. Carlyle is bidding through its newly formed healthcare investment platform Atmas Health, according to one of the sources. Medtronic has been taking offers for its patient monitoring and respiratory interventions businesses even as it presses on with preparations to spin them off to its shareholders. ICU Medical, GE Healthcare, Carlyle and CD&R declined to comment. The patient monitoring technology portfolio includes Nellcor pulse oximetry and BIS brain monitoring, while the respiratory interventions business comprises ventilators and breathing systems.

March 20 (Reuters) - U.S. scientific instruments maker Thermo Fisher Scientific Inc (TMO.N) and South Korea's Celltrion Inc (068270.KS) are among those competing to acquire the biopharma solutions business of medical device maker Baxter International Inc (BAX.N), according to people familiar with the matter. Baxter, which has a market value of $19 billion, had total debt of $16.6 billion as of the end of December. Private equity firms, including KKR & Co (KKR.N) and Carlyle Group (CG.O), have also expressed interest in the Baxter business, the sources said. Baxter said in January it was exploring alternatives for its biopharma solutions business and would also spin off its kidney care units. Baxter's biopharma solutions unit supports drugmakers in the formulation, development and commercialization of drugs typically given by infusion or injection, such as biologics and vaccines.

☆ Wall Street closes higher as First Republic helps lift banks
▼ + stars: | 2023-03-16 | by ( David Carnevali | ) www.reuters.com time to read: +3 min

SummarySummary Companies European Central Bank raises key policy rateFirst Republic Bank shares reverse course and turn higherMeta, Snap climb as U.S. threatens TikTok banNEW YORK, March 16 (Reuters) - A strong rebound by financials helped Wall Street's main indexes close firmly positive on Thursday, after some of the country's largest lenders came to the rescue of embattled First Republic Bank. "Banks are looking out for one another," said Huntington Private Bank chief investment officer, John Augustine. Shares of JP Morgan and Morgan Stanley were up 1.94% and 1.89% respectively, while the lifeline buoyed First Republic Bank (FRC.N), which gained 9.98%. The KBW regional banking index (.KRX) gained 3.26%, while the S&P 500 banking index (.SPXBK) advanced 2.16%, as both sub-indexes reversed losses. Concerns about banks have rattled the stock market in recent days after the collapse of SVB Financial fueled contagion fears.

☆ Wall Street down as Credit Suisse sparks fresh bank selloff
▼ + stars: | 2023-03-15 | by ( David Carnevali | ) www.reuters.com time to read: +4 min

I don’t think we are at 2008-2009 stages by any means when it comes to the contagion stuff," said Themis Trading co-manager of trading, Joe Saluzzi. Still, Credit Suisse troubles piled more pressure on U.S. banking sector after U.S. authorities relieved investors with emergency measures to prevent contagion after the collapse of SVB Financial (SIVB.O) and Signature Bank (SBNY.O). Some investors believe aggressive U.S. interest rate hikes by the Federal Reserve caused cracks in the financial system. Shares of Western Alliance Bancorp (WAL.N) and bank and brokerage Charles Schwab Corp (SCHW.N) bucked the trend to close in the green. Big U.S. banks including JPMorgan Chase & Co (JPM.N), Citigroup (C.N) and Bank of America Corp (BAC.N) dropped, dragging on the S&P 500 banking index (.SPXBK).

☆ Sliding bank shares drag Wall Street down in choppy trade
▼ + stars: | 2023-03-13 | by ( David Carnevali | ) www.reuters.com time to read: +4 min

But many speculated the central bank could now become less hawkish, and the yield on the 2-year Treasury tumbled. Shares of SVB's peer Signature Bank (SBNY.O), which was also shut down by regulators, were halted. Weighing on the S&P 500, Charles Schwab (SCHW.N) tumbled 11.56% upon resuming trade after the financial services company reported a 28% decline in average margin balances and a 4% fall in total client assets for February. Shares of big U.S. banks, including JPMorgan Chase & Co (JPM.N), Citigroup (C.N), and Wells Fargo (WFC.N) all lost ground. The S&P 500 posted 1 new 52-week highs and 48 new lows; the Nasdaq Composite recorded 29 new highs and 526 new lows.

Emerson dropped that threat once the sale process for National Instruments got underway. National Instruments ended trading on Thursday at $50.62 a share. National Instruments expects the sale process to be completed by early April, according to the sources. National Instruments, Fortive and Keysight did not immediately respond to requests for comment. Austin, Texas-based National Instruments specializes in the production of automated testing and measurement tools for the semiconductor, transportation, aerospace and defense industries.

Leonard Green is also considering the sale of a minority stake in Pro Mach as an alternative to an outright sale, one of the sources said. That would preserve Pro Mach's debt structure and would not require bidders to secure leveraged buyout financing, the source added. Leonard Green and Pro Mach did not immediately respond to requests for comment. Leonard Green bought Pro Mach from buyout firm AEA Investors LP for about $2.2 billion, including debt, in 2018. Moody's said in December that Pro Mach's order book indicated "healthy demand" for its products despite concerns of slowing economic growth.

Reuters reported in March 2020 that Syneos was working with investment bank Centerview Partners LLC to explore a sale. Syneos, which has a market capitalization of $3.9 billion and carries a $2.9 billion debt pile, was not immediately available for comment. Based in Morrisville, North Carolina, Syneos helps pharmaceutical companies with clinical trials and to market their drugs. There has been a wave of consolidation among contract research organizations in a bid to lower costs, amass more clinical trial data and win customers. Labcorp (LH.N), for example, said earlier this month that it will complete the spinoff of its contract research organization, called Fortrea, by the middle of this year.

Lawrence Elbaum, co-head of law firm Vinson & Elkins' shareholder activism practice, said investors were looking for value-boosting strategies that do not require much funding in a difficult market. Deka Investment, which has around 367 billion euros ($392 billion) in assets under management and holds stakes in most major German corporations, has repeatedly called out German companies for structural weaknesses. Germany's blue-chip DAX 30 index (.GDAXI) put in the worst performance of any major European stock market in the past year, rising just 2%. Joe Kaeser, supervisory board chairman of Siemens Energy (ENR1n.DE), said the United States was much more advanced, and also more successful, in the field of shareholder activism. As CEO of conglomerate Siemens AG from 2013 until 2021, he engineered one of Germany's most successful corporate break-ups, separately listing Siemens Energy and Siemens Healthineers (SHLG.DE) and merging Siemens's wind unit with Spain's Gamesa.

☆ Private equity acquires a taste for drug development
▼ + stars: | 2023-01-09 | by ( David Carnevali | ) www.reuters.com time to read: +6 min

Jan 9 (Reuters) - Private equity firms that deemed drug development too risky for their liking in the past are increasingly investing in the sector, raising dedicated funds and coming up with deals that compensate them for the uncertainty involved. These deals are not structured as the leveraged buyouts that private equity firms are mostly known for. In most cases, the drug makers start paying the money back to the private equity firms when the drug is being developed, either by issuing equity, tapping cash on hand or borrowing. They also share a slice of the newly developed drug's revenue with the private equity firms once it's approved. Private equity firms also provide capital to spin out drugs into new companies.

Dec 17 (Reuters) - L3Harris Technologies Inc (LHX.N) is nearing a $4.7 billion deal to acquire U.S. rocket maker Aerojet Rocketdyne Holdings Inc (AJRD.N), 10 months after the latter's $4.4 billion sale to Lockheed Martin Corp (LMT.N) fell through, people familiar with the matter said on Saturday. L3Harris is a defense contractor that is mostly a competitor rather than a customer of Aerojet. Aerojet's solid fuel rocket motors and other propulsion systems would help L3Harris expand its space defense systems and precision munitions businesses. Spokespeople for Aerojet, L3Harris and General Electric did not immediately respond to requests for comment. Its customers include the Pentagon, Boeing (BA.N), Lockheed Martin and Raytheon Technologies Corp (RTX.N).

☆ Direct ChassisLink changes hands in $3.6 billion deal-sources
▼ + stars: | 2022-12-15 | by ( ) www.reuters.com time to read: +1 min

The deal marks a win for Apollo, which acquired a majority stake in Charlotte, North Carolina-based Direct ChassisLink and logistics and digital supply chain solutions company Blume Global from EQT in 2019 for around $2.5 billion, including debt. Excluding Blume's remaining value, Apollo made two times the money it invested, according to a person familiar with the matter. Blume separately raised money from outside investors in 2021 at a valuation of $500 million. Direct ChassisLink controls a fleet of over 151,000 marine and 100,000 domestic chassis. Reporting by David Carnevali in New York; Editing by Josie KaoOur Standards: The Thomson Reuters Trust Principles.

Nov 30 (Reuters) - Industrial conglomerate General Electric Co (GE.N) and defense contractor L3Harris Technologies Inc (LHX.N) are among those competing to acquire rocket maker Aerojet Rocketdyne Holdings Inc (AJRD.N), according to people familiar with the matter. Aircraft producer Textron Inc (TXT.N) and private equity firm Veritas Capital are also vying to acquire El Segundo, California-based Aerojet, which has a market value of about $4 billion, the sources said. Aerojet has been running a process to sell itself after its $4.4 billion sale to Lockheed Martin Corp (LMT.N) was thwarted by antitrust regulators in February, Reuters has previously reported. Spokespeople for Aerojet, General Electric, Textron and Veritas Capital did not respond to requests for comment. Its customers include the Pentagon, Boeing (BA.N), Lockheed Martin and Raytheon Technologies Corp (RTX.N).

☆ EXCLUSIVE Carlyle seeks to line up bid for urgent care provider Heritage -sources
▼ + stars: | 2022-11-15 | by ( David Carnevali | ) www.reuters.com time to read: +3 min

Carlyle, a Washington, D.C.-based buyout firm, has been in discussions with other private equity firms about assembling a consortium that would make an offer to acquire HPN, the sources said. HPN generates annual cash flow of around $600 million, according to the sources. Merkin grew the Los Angeles-based company into a managed care powerhouse in the Californian market, where it serves nearly 700,000 individuals. Earlier this month, primary care provider VillageMD, which is backed by Walgreens Boots Alliance Inc (WBA.O), said it would acquire private equity-owned urgent care provider Summit Health in a deal valued at $9 billion. Amazon agreed in July to buy primary care provider One Medical for $3.49 billion, while CVS inked a deal in September to acquire Signify Health for $8 billion.

[1/2] The company logo for Johnson & Johnson is displayed to celebrate the 75th anniversary of the company's listing at the New York Stock Exchange (NYSE) in New York, U.S., September 17, 2019. J&J is focused on its pharmaceuticals and medical devices operations with the consumer health spinoff expected by November 2023. Chief Executive Joaquin Duato has said he will look to build up the medical devices unit through acquisition. Abiomed will operate as a standalone business within the healthcare conglomerate's medical technology division. J&J's medical technology business includes surgical, orthopedic and various other devices.

Oct 31 (Reuters) - Emerson Electric Co (EMR.N) will sell a majority stake in its climate technologies unit to Blackstone Inc (BX.N) in a deal that values the business at $14 billion, as the U.S. industrial firm pivots to supplying to a booming automation market. Emerson's shares edged up 1% in a weak broader market as the company also beat fourth-quarter earnings and revenue. The Climate Technologies business, which will be structured as a joint venture, generated net sales of $5 billion in fiscal 2022. Emerson said it plans to use proceeds from the deal to invest in automation-related businesses and spend around $2 billion on share repurchases in 2023. Centerview Partners LLC and Goldman Sachs are financial advisers to Emerson, while Barclays is the lead financial adviser to Blackstone.

The space company was valued at more than $1 billion when private equity firm AE Industrial Partners became its controlling shareholder in March. A FireFly spokesperson declined to comment when asked about the fundraising, as did a spokesperson for AE Industrial Partners. It is among a handful of U.S. space companies vying to launch small satellites into space. SpaceX's bigger Falcon 9 rocket costs $62 million and Rocket Lab's smaller Electron rocket costs $7 million. Venture capital investments in space companies fell 44% from a year earlier, according to a quarterly report from VC firm Space Capital.

☆ EXCLUSIVE Rocket maker Aerojet solicits acquisition offers -sources
▼ + stars: | 2022-10-25 | by ( David Carnevali | ) www.reuters.com time to read: +2 min

Aerojet, which is providing propulsion engines for NASA's Artemis 1 moon rocket, is working with advisers on an auction process and asked for indications of acquisition interest earlier this month, the sources said. Aerojet develops and manufactures liquid and solid rocket propulsion and hypersonic engines for space, defense, civil and commercial applications. Its customers include the Pentagon, Boeing (BA.N), Lockheed Martin and Raytheon Technologies Corp (RTX.N). Activist hedge fund Elliott Investment Management disclosed it had accumulated a 3.7% stake in Aerojet in August. Aerojet Chief Executive Eileen Drake said in September that "low to mid-single-digit" sales growth was most probable for the company this year.

☆ Payments tech firm Super Apps to list in U.S. via $1.1 bln SPAC deal
▼ + stars: | 2022-10-19 | by ( Makiko Yamazaki | David Carnevali | ) www.reuters.com time to read: 1 min

Oct 19 (Reuters) - Super Apps Holdings said on Wednesday it would go public in the United States through a merger with a special purpose acquisition company, in a deal that values the Malaysian payments technology firm at $1.1 billion. Register now for FREE unlimited access to Reuters.com RegisterReporting by Niket Nishant in Bengaluru; Editing by Shinjini GanguliOur Standards: The Thomson Reuters Trust Principles.

☆ Investor Elliott has taken stake in Germany's Fresenius -Bloomberg
▼ + stars: | 2022-10-19 | by ( Makiko Yamazaki | David Carnevali | ) www.reuters.com time to read: 1 min

FRANKFURT, Oct 19 (Reuters) - Elliott Investment Management has taken a stake in Fresenius SE (FREG.DE), seeking to potentially break up the diversified healthcare company, Bloomberg cited people familiar with the matter as saying. Fresenius and Elliott were not immediately available for comment. Shares in the company, which is controlled by charitable trust Else Kroener Fresenius-Stiftung, were up 9% at 1202 GMT. Fresenius controls the world's largest dialysis company Fresenius Medical Care (FMEG.DE). Register now for FREE unlimited access to Reuters.com RegisterReporting by Ludwig Burger, Patricia Weiss and Hans Seidenstuecker, editing by Kirsti KnolleOur Standards: The Thomson Reuters Trust Principles.

Search resuls for: "David Carnevali"

25 mentions found